• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Implants

Abbott reports sustained benefits with Esprit drug-eluting stent

November 4, 2024 By Sean Whooley

Abbott Esprit BTK

Abbott (NYSE:ABT) today announced data demonstrating the long-term effectiveness of its Esprit BTK drug-eluting stent. The everolimus-eluting resorbable scaffold system treats chronic limb-threatening ischemia (CLTI) below the knee (BTK). Abbott designed it to keep arteries open and deliver everolimus to support vessel healing prior to completely dissolving. The first-of-its-kind stent provides support to the vessel […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Implants, Stents, Vascular Tagged With: abbott

Elixir Medical has positive data for drug-eluting bioadaptive implant

October 29, 2024 By Sean Whooley

Elixir-Dynamx

Elixir Medical announced positive data demonstrating the benefit of its DynamX coronary bioadaptor system in target lesion failure (TLF). Data highlighted the success of DynamX compared to Medtronic’s Resolute Onyx zotarolimus drug-eluting stent (DES). The study looked at complex patient populations within the INFINITY-SWEDEHEART randomized controlled trial. Data included an analysis of patients with acute […]

Filed Under: Clinical Trials, Drug-Device Combinations, Implants, Stents Tagged With: Elixir Medical Corporation

Senseonics announces $16M registered direct offering

October 25, 2024 By Sean Whooley

Senseonics logo

Senseonics (NYSE:SENS) announced today that it entered into a definitive agreement to offer $16 million in common stock. Germantown, Maryland-based Senseonics plans to offer more than 45.7 million shares of common stock. It priced the shares at 35¢ per share in a registered direct offering. In a concurrent private placement, the company agreed to issue […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Funding Roundup, Implants, Patient Monitoring, Technology Tagged With: Senseonics

SpyGlass Pharma shares positive data for drug-eluting intraocular lens

October 18, 2024 By Sean Whooley

SpyGlass Pharma Intraocular Lens IOL drug delivery platform

SpyGlass Pharma released 18-month follow-up data highlighting the potential of its intraocular lens (IOL)-based drug delivery platform. Data came from a first-in-human study of 23 patients with glaucoma or ocular hypertension. They received the IOL implant at the time of cataract surgery. The company reported a consistent sustained reduction of intraocular pressure (IOP) across all […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Optical/Ophthalmic Tagged With: SpyGlass Pharma

Medinol has first human implant of drug-eluting peripheral stent in Australia

October 7, 2024 By Sean Whooley

Medinol ChampioNIR drug-eluting stent

Medinol today announced the successful first-in-human implantation of its ChampioNIR drug-eluting peripheral stent. Dr. Gerard S. Goh and Dr. Thodur Vasudevan of the Alfred Hospital in Melbourne, Australia, completed the stent implant. The company says it introduces a “revolutionary advancement” in the mechanics, durability and drug delivery of peripheral drug-eluting stents. Tel Aviv, Israel-based Medinol […]

Filed Under: Clinical Trials, Drug-Device Combinations, Implants, Stents, Vascular Tagged With: medinol

Vivani can begin first-in-human GLP-1 implant trial in Australia following regulatory approval

September 26, 2024 By Sean Whooley

Vivani NanoPortal diabetes implant

Vivani Medical (Nasdaq:VANI) today announced that Australian authorities approved a first-in-human clinical trial for its subdermal GLP-1 implant. The LIBERATE-1 trial will evaluate the miniature GLP-1 (exenatide) implant in obese and overweight subjects. This follows FDA approval for an investigational new drug (IND) application for the company’s implant in June. The FDA lifted the clinical hold […]

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Implants, Regulatory/Compliance Tagged With: Vivani Medical

CereVasc data shows that eShunt could help deliver gene therapies to the central nervous system

September 26, 2024 By Sean Whooley

cerevasc-eshunt

CereVasc shared data from a study demonstrating that its eShunt system may help deliver gene therapies to the central nervous system (CNS). eShunt, a minimally invasive system, includes an endovascularly implantable cerebral spinal fluid shunt and delivery components. CereVasc designed the system to enable transvenous-transdural access to the CNS to treat communicating hydrocephalus (CH) without […]

Filed Under: Clinical Trials, Drug-Device Combinations, Implants, Neurological Tagged With: CereVasc

Senseonics wins FDA nod for 365-day implantable CGM

September 17, 2024 By Sean Whooley

Senseonics Eversense 365 Product Image

Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system. Eversense 365, an implantable continuous glucose monitor (CGM), becomes the world’s first 365-day CGM system, according to the company. Its indications cover people with type 1 and type 2 diabetes aged 18 years and older. The system also received clearance […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, Patient Monitoring, Regulatory/Compliance, Technology Tagged With: Ascensia Diabetes Care, FDA, Senseonics

CorFlow Therapeutics raises $48.5M for diagnostic, drug delivery platform

September 10, 2024 By Sean Whooley

CorFlow Logo (1)

CorFlow Therapeutics announced today that it raised €44 million ($48.5 million) to support its novel diagnostic and drug delivery platform. Broadview Ventures and Panakes Partners led the financing round. 415 Capital, Merieux Equity Partners, Merieux Equity Partners, Laerdal Million Lives Fund, Wellington Partners, M&L Investments, Unorthodox Ventures, KOFA Healthcare and Monte Carlo Capital also participated. […]

Filed Under: Business/Financial News, Cardiovascular, Clinical Trials, Diagnostics, Drug-Device Combinations, Funding Roundup, Implants Tagged With: CorFlow

Elutia announces first implant of drug-eluting bioenvelope for pacemakers and neurostimulators

September 6, 2024 By Sean Whooley

Elutia EluPro drug-eluting bioenvelope (1)

Elutia (Nasdaq:ELUT) announced the first-ever patient implant of its EluPro drug-eluting biologic envelope cleared by the FDA. Dr. John Catanzaro of the East Carolina University Health Medical Center in Greenville, North Carolina, performed the first procedure. Elutia says this marks the first implant of the world’s first antibiotic-eluting biologic envelope. Elutia designed EluPro to prevent […]

Filed Under: Business/Financial News, Cardiovascular, Drug-Device Combinations, Featured, Implants, Neurological Tagged With: Elutia

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Interim pages omitted …
  • Page 23
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS